| Literature DB >> 33723998 |
P Holland Alday1, Erin V McConnell1, Jan M Boitz Zarella1, Rozalia A Dodean1, Papireddy Kancharla2, Jane X Kelly1,2, J Stone Doggett1.
Abstract
Acridone derivatives, which have been shown to have in vitro and in vivo activity against Plasmodium spp, inhibit Toxoplasma gondii proliferation at picomolar concentrations. Using enzymatic assays, we show that acridones inhibit both T. gondii cytochrome bc1 and dihydroorotate dehydrogenase and identify acridones that bind preferentially to the Qi site of cytochrome bc1. We identify acridones that have efficacy in a murine model of systemic toxoplasmosis. Acridones have potent activity against T. gondii and represent a promising new class of preclinical compounds.Entities:
Keywords: acridone; cytochrome bc1; dihydroorotate dehydrogenase; drug discovery; toxoplasma
Year: 2021 PMID: 33723998 PMCID: PMC8273083 DOI: 10.1021/acsinfecdis.1c00016
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084